about
Inhibition of topoisomerase I prevents chromosome breakage at common fragile sitesEn masse nascent transcription analysis to elucidate regulatory transcription factors.High-content chemical and RNAi screens for suppressors of neurotoxicity in a Huntington's disease modelMolecular Cloning, Heterologous Expression, and Functional Characterization of an NADPH-Cytochrome P450 Reductase Gene from Camptotheca acuminata, a Camptothecin-Producing PlantThe structure–activity relationships of A-ring-substituted aromathecin topoisomerase I inhibitors strongly support a camptothecin-like binding modeExploring the cellular activity of camptothecin-triple-helix-forming oligonucleotide conjugates.Practical synthesis of (20S)-10-(3-aminopropyloxy)-7-ethylcamptothecin, a water-soluble analogue of camptothecin.High-content screening and profiling of drug activity in an automated centrosome-duplication assay.Design, synthesis, and biological evaluation of O-2-modified indenoisoquinolines as dual topoisomerase I-tyrosyl-DNA phosphodiesterase I inhibitors.A novel norindenoisoquinoline structure reveals a common interfacial inhibitor paradigm for ternary trapping of the topoisomerase I-DNA covalent complex.Structural simplification of bioactive natural products with multicomponent synthesis. 3. Fused uracil-containing heterocycles as novel topoisomerase-targeting agentsDesign and synthesis of new 7-(N-substituted-methyl)-camptothecin derivatives as potent cytotoxic agents.Perspectives on biologically active camptothecin derivatives.Cellular basis of antiproliferative and antitumor activity of the novel camptothecin derivative, gimatecan, in bladder carcinoma models.Alcohol-, diol-, and carbohydrate-substituted indenoisoquinolines as topoisomerase I inhibitors: investigating the relationships involving stereochemistry, hydrogen bonding, and biological activity.Molecular and cellular pharmacology of the novel noncamptothecin topoisomerase I inhibitor Genz-644282.Design and synthesis of novel spin-labeled camptothecin derivatives as potent cytotoxic agentsSecondary metabolites as DNA topoisomerase inhibitors: A new era towards designing of anticancer drugs.A small molecule screen identifies in vivo modulators of peripheral nerve regeneration in zebrafish.Identification, synthesis, and biological evaluation of metabolites of the experimental cancer treatment drugs indotecan (LMP400) and indimitecan (LMP776) and investigation of isomerically hydroxylated indenoisoquinoline analogues as topoisomerase ISynthesis and biological evaluation of new fluorinated and chlorinated indenoisoquinoline topoisomerase I poisons.Assessing the regioselectivity of OleD-catalyzed glycosylation with a diverse set of acceptors.An ab initio quantum mechanics calculation that correlates with ligand orientation and DNA cleavage site selectivity in camptothecin-DNA-topoisomerase I ternary cleavage complexes.Total synthesis and biological evaluation of 22-hydroxyacuminatine.Design, synthesis, and biological evaluation of 14-substituted aromathecins as topoisomerase I inhibitorsA stabilizer-free and organic solvent-free method to prepare 10-hydroxycamptothecin nanocrystals: in vitro and in vivo evaluation.The cell's nucleolus: an emerging target for chemotherapeutic intervention.Design, Synthesis, and Biological Evaluation of Potential Prodrugs Related to the Experimental Anticancer Agent Indotecan (LMP400).Synthesis and biological evaluation of new carbohydrate-substituted indenoisoquinoline topoisomerase I inhibitors and improved syntheses of the experimental anticancer agents indotecan (LMP400) and indimitecan (LMP776).Combinatorial biosynthesis in plants: a (p)review on its potential and future exploitation.Design, synthesis and potent cytotoxic activity of novel 7-(N-[(substituted-sulfonyl)piperazinyl]-methyl)-camptothecin derivatives.Topoisomerase IIα poisoning and DNA double-strand breaking by chiral ruthenium(ii) complexes containing 2-furanyl-imidazo[4,5-f][1,10]phenanthroline derivatives.From Lead to Drug Utilizing a Mannich Reaction: The Topotecan Story.Synthesis and optimization of a bifunctional hyaluronan-based camptothecin prodrug.Comparison of the effects of photon versus carbon ion irradiation when combined with chemotherapy in vitro.Anti-Cancer Phytometabolites Targeting Cancer Stem CellsCamptothecin-7-yl-methanthiole: semisynthesis and biological evaluation.Synthesis and biological evaluation of 7-alkenyl homocamptothecins as potent topoisomerase I inhibitors.Supramolecular nanostructures formed by anticancer drug assembly.Efficient intracellular delivery of camptothecin by silica/titania hollow nanoparticles.
P2860
Q24622097-E23F8297-9E64-428B-B1C4-53047F0B263FQ25255974-CA4CD082-8886-4359-96AC-5E31B8C2A321Q27323092-FB034E6A-B9BA-4474-A200-52C860BA60EEQ28547104-D235A365-3FE1-4F08-A1DA-37CA01CD01AAQ29028715-049A1359-5FE2-4EA5-BB14-1856B24361B5Q30446938-3C42F3C0-97C1-4103-A0FE-FE43CA89C929Q30583944-6A38631E-2707-40F6-BD34-1C109AB19AEEQ31132684-F82A9CC2-B0A6-4A0A-9F12-670FCAC76BD0Q33662415-E3CB5C46-D240-47F3-9C0F-CE9573BDA76FQ33812633-B59790D3-8E81-4CB8-8C8F-D0497509EBDEQ33841304-2D628AEA-65F1-43BB-99BE-2BEEAC31641CQ34036266-105B69D8-E44D-4813-9317-1EB4C1B5ED7FQ34468628-3239BD6D-0A74-4332-8090-319A06638A7DQ34768288-A0724BB0-0E8E-4070-B371-6E6AC0F81C3BQ35152039-2D293592-5B05-4D6D-B690-5643FB804008Q35161740-20418F15-9D8D-4B4A-B43A-2AEBC8BC8DC6Q35170548-7B9DB9D1-814B-4675-B6D9-F24E1CFC9682Q35646690-A3F8FFC8-C00E-436E-A066-51320096F204Q36390956-008E4635-7DFC-4C6F-8866-8525A431D0A5Q36525254-BFFAB9BD-2B85-4DEC-8A8C-37C3B3173FEAQ36680167-43DC8F17-D47E-4630-A50D-A97C9905C6AEQ36715634-08F41DB2-21A4-4A76-B5D2-38BFB1D49782Q36853869-7489542C-7410-4AC9-B8F5-77ECA99F07CBQ36867857-C8645195-00EE-445D-9E69-47D6CC02B0B1Q36882373-014EA876-97D1-436B-A9C0-B328B7F0E2A6Q37042592-59C573DF-C92E-4344-833C-CF493320E1AEQ37484539-AD92CFFB-466F-4E73-948C-3330F1A730D9Q37652515-38F901CF-38EF-40DD-963A-50E1C805E004Q37697354-2B2A749D-D4B5-4587-8DFC-ABFAF5B4E395Q37939609-8503CCB4-6004-45DB-93DF-96246744E442Q38712547-49328CDC-D141-4EDC-B6BC-E3B02D4E959DQ38768406-18AEEB89-3539-4AA7-94FF-31A582AD7BA5Q38996735-7AE247C4-E1D4-4EB9-B289-8C8708D64E9FQ39036296-E286F56F-9ACE-4A64-9777-983EB72C1F5BQ39066862-D200A3BF-2C14-4E04-A386-5229EE1808FCQ39214227-C5393EA4-7737-4AAF-8803-45149FCF43C0Q39255471-D6090425-065A-42DA-95D7-8E6AED34210CQ39331081-B6DE4066-B225-4E51-A707-12EB871CEA4BQ39361804-B29937C3-7C12-417C-B022-84364630A84CQ39378811-4E0904E5-A90B-4D36-BFF1-8D0477EA9581
P2860
description
2004 nî lūn-bûn
@nan
2004 թուականի Ապրիլին հրատարակուած գիտական յօդուած
@hyw
2004 թվականի ապրիլին հրատարակված գիտական հոդված
@hy
2004年の論文
@ja
2004年論文
@yue
2004年論文
@zh-hant
2004年論文
@zh-hk
2004年論文
@zh-mo
2004年論文
@zh-tw
2004年论文
@wuu
name
Camptothecin: current perspectives.
@ast
Camptothecin: current perspectives.
@en
type
label
Camptothecin: current perspectives.
@ast
Camptothecin: current perspectives.
@en
prefLabel
Camptothecin: current perspectives.
@ast
Camptothecin: current perspectives.
@en
P2093
P1476
Camptothecin: current perspectives.
@en
P2093
Craig J Thomas
Nicolas J Rahier
Sidney M Hecht
P304
P356
10.1016/J.BMC.2003.11.036
P407
P577
2004-04-01T00:00:00Z